GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (XSWX:QGEN) » Definitions » EV-to-FCF

Qiagen NV (XSWX:QGEN) EV-to-FCF : 40.31 (As of Apr. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Qiagen NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Qiagen NV's Enterprise Value is CHF10,656 Mil. Qiagen NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF264 Mil. Therefore, Qiagen NV's EV-to-FCF for today is 40.31.

The historical rank and industry rank for Qiagen NV's EV-to-FCF or its related term are showing as below:

XSWX:QGEN' s EV-to-FCF Range Over the Past 10 Years
Min: 15.65   Med: 36.91   Max: 1472.45
Current: 32.58

During the past 13 years, the highest EV-to-FCF of Qiagen NV was 1472.45. The lowest was 15.65. And the median was 36.91.

XSWX:QGEN's EV-to-FCF is ranked worse than
59.62% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.56 vs XSWX:QGEN: 32.58

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Qiagen NV's stock price is CHF41.45. Qiagen NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.000. Therefore, Qiagen NV's PE Ratio for today is N/A.


Qiagen NV EV-to-FCF Historical Data

The historical data trend for Qiagen NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV EV-to-FCF Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 154.93 86.48 31.26 20.89 35.01

Qiagen NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.89 25.71 28.77 35.27 35.01

Competitive Comparison of Qiagen NV's EV-to-FCF

For the Diagnostics & Research subindustry, Qiagen NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Qiagen NV's EV-to-FCF falls into.



Qiagen NV EV-to-FCF Calculation

Qiagen NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10656.128/264.351
=40.31

Qiagen NV's current Enterprise Value is CHF10,656 Mil.
Qiagen NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF264 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qiagen NV  (XSWX:QGEN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Qiagen NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=41.45/0.000
=N/A

Qiagen NV's share price for today is CHF41.45.
Qiagen NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Qiagen NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Qiagen NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (XSWX:QGEN) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).